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ABSTRACT
Objective To describe the patterns and clinical features
of toxicity related to recreational use of mephedrone and
other cathinones in the UK using data collected by the
National Poisons Information Service (NPIS).
Methods The number of accesses to TOXBASE, the
NPIS online poisons information database, details of
consecutive cases uploaded onto TOXBASE and the
number and details of telephone enquiries made to the
NPIS by health professionals in the UK were collected for
the period March 2009 to February 2010.
Results Over the year of study there were 2901
TOXBASE accesses and 188 telephone enquiries relating
to cathinones, the majority relating to mephedrone
(TOXBASE 1664, telephone 157), with a month-on-
month increase in numbers. In 131 telephone enquiries
concerning mephedrone, alone or in combination with
alcohol, common clinical features reported included
agitation or aggression (n¼32, 24%, 95% CI 18% to
33%), tachycardia (n¼29, 22%, 95% CI 16% to 30%),
confusion or psychosis (n¼18, 14%, 95% CI 9% to 21%),
chest pain (n¼17, 13%, 95% CI 8% to 20%), nausea
(n¼15, 11%, 95% CI 7% to 18%), palpitations (n¼14,
11%, 95% CI 6% to 18%), peripheral vasoconstriction
(n¼10, 8%, 95% CI 4% to 14%) and headache (n¼7,
5%, 95% CI 2% to 11%). Convulsions were reported in
four cases (3%, 95% CI 1% to 8%). One exposed person
died following cardiac arrest (1%, 95% CI 0% to 4%),
although subsequent investigation suggested that
mephedrone was not responsible.
Conclusions Toxicity associated with recreational
mephedrone use is increasingly common in the UK.
Sympathomimetic adverse effects are common and
severe effects are also reported. Structured data
collected by the NPIS may be of use in identifying trends
in poisoning and in establishing toxidromes for new drugs
of abuse.
INTRODUCTION
Mephedrone (4-methylmethcathinone, 4-MMC) is
one of several synthetic cathinones structurally
related to the naturally occurring phenylpropyl-
amine alkaloid cathinone found in the khat plant
(Catha edulis).
1 This is commonly chewed for its
stimulant properties in Somalia and Yemen. Cath-
inones are b-ketoamfetamine derivatives which
possess a ketone group at the b carbon position of
the amfetamine backbone (ﬁgure 1).
1 While cath-
inone and some of its derivatives are controlled
under misuse of drugs regulations in the UK,
mephedrone has not been controlled
2 until April
2010 when it became classiﬁed as a class B drug. It
also remains legal in many other countries world-
wide. Synthetic cathinones including mephedrone
have been freely available and inexpensive for
purchase as research chemicals or plant foods in
‘head shops’ and especially via the internet.
Other than some preliminary data on routes of
metabolism in rodents and humans,
3 4 information
currently available about the pharmacology of
mephedrone is extremely limited although, as
would be expected from their chemical similarity,
the properties of other cathinones resemble closely
those of amfetamines.
5e8 However, although it has
been suggested that signiﬁcant structureeactivity
similarities exist between speciﬁc cathinones and
their amfetamine analogues, caution should be used
in attempting to draw conclusions or make
predictions about the activity and potency of
individual analogues.
9
Severe clinical effects and deaths apparently
associated with mephedrone have been reported
widely in the media
2 although, to date, analytical
conﬁrmation of mephedrone exposure has only
been established in a few cases.
11 0
The National Poisons Information Service (NPIS)
provides information and advice to health profes-
sionals in the UK about the management of
poisoning via information held on its website
TOXBASE
11 and by answering enquiries made by
telephone. Over the last year the NPIS has received
increasing numbers of enquiries relating to
synthetic cathinones, predominantly mephedrone.
This paper describes the epidemiology and clinical
effects of poisoning with these agents as reported
to the NPIS by the healthcare professionals
involved in their care.
METHODS
TOXBASE accesses and telephone enquiry data
relating to mephedrone and other synthetic cath-
inones were sought for the year 1 March 2009 to
28th February 2010. Data for methylenedioxy-
methamfetamine (MDMA, ‘ecstasy’) and cocaine
were also extracted for comparison.
TOXBASE accesses were quantiﬁed for clinical
users within the UK, excluding users from Ireland,
other overseas countries, the Channel Islands and
the Isle of Man. Users within the ‘Educational’ (eg,
medical schools) and ‘Government Ofﬁce’ cate-
gories were also excluded, as well as those from
NPIS units, to avoid double counting. Accesses
were classiﬁed into ‘sessions’ to consolidate
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Original articlemultiple instances of the same entry being accessed during the
same session.
TOXBASE provides the opportunity for health professionals
to upload structured clinical information about exposures,
12
including those involving new or uncommon agents. Informa-
tion uploaded for cathinones since these entries were added to
TOXBASE (table 1) was also collated.
Telephone enquiries to the NPIS are handled by information
scientists from the four NPIS units in Birmingham, Cardiff,
Edinburgh and Newcastle. Clinical details provided by the
enquirer are recorded on the stored on the UK Poisons Infor-
mation Database which is held on a central server, allowing
rapid access to information collected nationally. Data on
demographic characteristics (age, sex), severity and clinical
features of poisoning relating to mephedrone and other cath-
inones as reported by enquirers were extracted from the UK
Poisons Information Database. Ethical approval was not
required for this study since involved analysis of routinely
collected clinical information.
RESULTS
The numbers of telephone and TOXBASE enquiries relating to
synthetic cathinones increased steeply over the year of the
study, especially those involving mephedrone which has recently
become more commonly involved in enquiries than MDMA or
cocaine (ﬁgure 2). Telephone enquiry numbers for cocaine and
MDMA declined over the course of the year.
Over the study period the NPIS handled telephone enquiries
from about 188 people reported to be exposed to cathinones
(table 1). Of these, 157 involved mephedrone and in 131 (77
males, 49 females, 5 sex not known; median age 20 years) the
drug was reported to have been used alone or in combination
with alcohol only. In the remaining 26 cases other agents were
also reported to be involved, including cocaine (n¼13), cannabis
(n¼6), amfetamine, ketamine, growth hormone, buprenorphine,
risperidone, quetiapine and methedrone (n¼1 for each).
Details of 27 episodes involving cathinones (23 mephedrone, 4
methedrone) have also been uploaded by health professionals
onto TOXBASE. In 18 of these cases (13 males, 7 females,
median age 20 years) mephedrone was used alone or with
alcohol and in ﬁve cases it was used in combination with other
agents (cocaine, diazepam, heroin, amfetamine, cannabis,
triﬂuoperazine).
Clinical features reported in the cases involving mephedrone
taken alone or in combination with alcohol are shown in table 2.
Because the methods of data collection are different, telephone
enquiry data and TOXBASE upload data are shown separately.
For telephone enquiries, ingestion was more common than
insufﬂation (‘snorting’), while in the cases uploaded to
TOXBASE, insufﬂation was more common although details of
route of exposure were often not provided. The median meph-
edrone dose reported was 1 g for both telephone enquiries
(n¼30) and TOXBASE reports (n¼8). In telephone enquiries the
median dose was 1 g for both ingestion (n¼19) and insufﬂation
(n¼11). In most cases, however, this information was not
available or not provided.
The most common clinical features reported by health
professionals with mephedrone exposure were those typical for
a sympathomimetic agent including tachycardia, palpitations,
agitation, anxiety, mydriasis, tremor, fever or sweating and
hypertension (table 2). Some patients reported features
suggesting peripheral vasoconstriction such as white or blue
extremities which were sometimes painful. Other common
features included nausea, breathlessness, dizziness and headache.
Skin rashes and local effects in the mouth, pharynx or nose were
also occasionally reported. Symptoms were often reported to be
prolonged after mephedrone exposure (table 2).
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Figure 1 Chemical structures.
Table 1 TOXBASE accesses and telephone enquiries relating to selected stimulants March 2009eFebruary 2010
Substance Synonyms
TOXBASE accesses Telephone enquiries
Date of entry on TOXBASE n n
Mephedrone 4-methylmethcathinone, 4-MMC, MCAT,
‘bubbles’, ‘meow’, ‘sub coca’,
‘methylamino’, ‘drone’, ‘meph’
July 2009 1664 157
Methedrone Methoxymethcathinone, bk-PMMA,
PMMA, ‘methoxymethcath’
Nov 2009 618 6
Methylone bk-MDMA, ‘methylene dioxy’ Nov 2009 53 6
Methcathinone ephedrone, m-cat, methylcathinone Oct 2009 566 0
Ethylone bk-MDEA, MDEC No entry e 0
Butylone bk-MBDB No entry e 2
Methylenedioxy-pyrovalerone MDPV, hyperfocusine No entry e 11
Methelenedioxy-methamfetamine MDMA, ‘Ecstasy’ Throughout study 3524 151
Cocaine Throughout study 3707 196
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associated with ECG changes suggesting acute myocardial
infarction. Confusion and/or psychosis were also frequent.
Three patients were reported to have generalised convulsions; in
one episode this was following an apparent cardiac arrest and in
two episodes no prior history of epilepsy was recorded. A further
patient was described as having focal convulsions and another
patient had undiagnosed blackouts. In other episodes convul-
sions were not reported but a reduced level of consciousness or
raised creatine kinase was documented. There were also occa-
sional reports of acidosis and abnormal liver function tests
(raised transaminases) and a single report of spontaneous
pneumomediastinum associated with insufﬂation.
One NPIS enquiry was made during unsuccessful resuscita-
tion attempts following an apparent cardiac arrest in a patient
exposed to mephedrone.
DISCUSSION
NPIS data have a number of limitations that need to be
considered in interpretation. Enquiry numbers are not a direct
measurement of patient presentations to hospital since advice is
more likely to be sought for sicker patients or when unfamiliar
agents are involved. The data analysed relies on users and
healthcare professionals knowing and providing accurate infor-
mation on the agents involved since toxicological conﬁrmation
is not generally available. A particular problem in this respect is
the similarity of drug names, which may be confused. Clinical
features may be underestimated because they are not reported or
recorded at the time of enquiry or because they occur after an
enquiry has been made. Incomplete follow-up of enquiries
results in limited information being available about later
complications or ﬁnal outcome. Information uploaded to
TOXBASE by health professionals is more likely to be complete
than telephone data, but patients with more severe or unusual
outcomes may be more likely to be reported. For both methods
the reported clinical features may reﬂect the effects of other
agents used concurrently and details of these agents may not be
reported.
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Figure 2 (A) TOXBASE accesses and (B) telephone enquiries relating
to selected stimulants during study period.
Table 2 Clinical features reported with exposure to mephedrone alone
or in combination with alcohol as reported in telephone enquiries
(n¼131) or uploaded to TOXBASE (n¼18)
Telephone enquiries
TOXBASE
reports
n % (95% CI) n % (95% CI)
Route of exposure
Ingestion 69 53 (44 to 61) 2 11 (2 to 36)
Insufﬂation 42 32 (24 to 41) 5 28 (11 to 54)
Parenteral 2 2 (0 to 6) 0 0 (0 to 22)
Other/multiple 2 2 (0 to 6) 2 11 (2 to 36)
Not known 16 12 (5 to 16) 9 50 (26 to 73)
Clinical features
Agitation, aggression 32 24 (18 to 33) 9 50 (26 to 73)
Tachycardia 29 22 (16 to 30) 7 39 (18 to 64)
Anxiety 19 15 (9 to 22) 3 17 (4 to 42)
Confusion, psychosis 18 14 (9 to 21) 3 17 (4 to 42)
Chest pain 17 13 (8 to 20) 5 28 (11 to 54)
No features 17 13 (8 to 20) 3 17 (4 to 42)
Nausea 15 11 (7 to 18) 4 22 (7 to 48)
Palpitations 14 11 (6 to 18) 5 28 (11 to 54)
Fever, sweating 12 9 (5 to 16) 2 11 (2 to 36)
Breathlessness 11 8 (4 to 15) 2 11 (2 to 36)
Dizziness 10 8 (4 to 14) 2 11 (2 to 36)
Peripheral vasoconstriction 10 8 (4 to 14) 1 6 (3 to 29)
Mydriasis 9 7 (3 to 13) 2 11 (2 to 36)
Skin changes, rash 9 7 (3 to 13) 1 6 (3 to 29)
Headache 7 5 (2 to 11) 3 17 (4 to 42)
Reduced level of consciousness 7 5 (2 to 11) 4 22 (7 to 48)
Abdominal pain 6 5 (2 to 10) 2 11 (2 to 36)
Hypertension 5 4 (1 to 9) 0 0 (0 to 22)
Parasthesiae 5 4 (1 to 9) 0 0 (0 to 22)
Insomnia 5 4 (1 to 9) 0 0 (0 to 22)
Convulsions 4 3 (1 to 8) 2 11 (2 to 36)
Loin pain 4 3 (1 to 8) 1 6 (3 to 29)
Tongue disorder 4 3 (1 to 8) 0 0 (0 to 22)
Myoclonus/abnormal movements 3 2 (1 to 7) 2 11 (2 to 36)
Tremor 3 2 (1 to 7) 2 11 (2 to 36)
ECG abnormal 3 2 (1 to 7) 0 0 (0 to 22)
Local effects (mouth/pharynx) 3 2 (1 to 7) 0 0 (0 to 22)
Dystonic reaction 2 2 (1 to 7) 0 0 (0 to 22)
Abnormal vision 2 2 (1 to 7) 1 6 (3 to 29)
Liver function tests abnormal 2 2 (1 to 7) 0 0 (0 to 22)
Raised creatine kinase 1 1 (0 to 4) 3 17 (4 to 42)
Acidosis 1 1 (0 to 4) 1 6 (3 to 29)
Epistaxis 1 1 (0 to 4) 1 6 (3 to 29)
Renal function abnormal 1 1 (0 to 4) 0 0 (0 to 22)
Death 1 1 (0 to 4) 0 0 (0 to 22)
Persistence of symptoms after exposure
>24 h 59 45 (36 to 54) 4 22 (7 to 48)
>48 h 39 30 (22 to 38) 1 6 (3 to 29)
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structured datacollected bytheNPIS may be ofuse in identifying
trends in poisoning and in establishing toxidromes for new drugs
of abuse. Enquiries relating to mephedrone in particular have
becomecommonplaceintheUK,reﬂectingasubstantialworkload
for healthcare professionals, especially those working in emer-
gency departments. This may be partly offset by reductions in
presentations associated with other stimulants such as MDMA
and cocaine, although it is too early to draw reliable conclusions.
Most mephedrone exposures are not associated with severe
toxicityalthough, aspredicted from its amfetamine-like chemical
structure, sympathomimetic effects are common and have been
described previously in one case of conﬁrmed mephedrone expo-
sure
13 and in a series of exposed people attending an emergency
department in London.
1 A similar pattern of common effects was
also reported from a survey of users, with sweating, headaches,
nausea, palpitations and cold or blue ﬁngers being common.
14
The occurrence of severe features including hallucinations,
chest pains and convulsions is of particular concern. The
reported episode of apparent myocardial infarction is of interest;
it is not possible to demonstrate causality from this single
report, but an increased risk of myocardial infarction has been
reported in users of khat.
15 Other effects such as confusion, fever
or myoclonus may reﬂect serotoninergic actions of the drug.
One patient in this series died having experienced cardiac
arrest, apparently in the context of mephedrone use, but
subsequent investigation suggested that mephedrone was not
responsible. Deaths have previously been reported in mephe-
drone users and in some cases toxicological conﬁrmation of the
presence of mephedrone is available,
1 10 although this does not
prove that death was caused by mephedrone exposure.
It is of interest that clinical features, including severe effects,
sometimes appear to persist for (or occur) more than 24 h after
the most recent reported exposure. The explanation for this is
unclear; elimination of other cathinones appears rapid, with
elimination half-lives in humans reported as 1.5e2.3 h for
cathinone and 5.2 h for cathine.
7 16 Pharmacokinetic informa-
tion is not currently available for mephedrone. For amfetamines,
repetitive use has been reported to increase the apparent half-life
and duration of effect.
17
NPIS data are not helpful for predicting the longer term toxic
effects of mephedrone, but available data for other cathinones
are not reassuring. Use of Khat has been associated with an
increased risk of psychosis
18 while methcathinone (ephedrone),
a dopamine and serotonin transporter substrate, reduces frontal
concentrations of dopamine and serotonin
19 and has toxic
actions against dopaminergic and serotoninergic neurons.
20 A
Parkinsonian syndrome has been reported in the intravenous use
of methcathinone synthesised from pseudoephedrone using
potassium permanganate, although this appears to result from
chronic manganese toxicity rather than as a direct neurotoxic
effect of the cathinone.
21
It remains to be seen what effects recent changes in legal
status may have on the pattern of presentations associated with
the toxicity of mephedrone and other cathinones. In the
meantime, health professionals, especially those working in
emergency departments and drug rehabilitation services, should
be aware of mephedrone and its acute toxic effects.
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